Corante

About this Author
DBL%20Hendrix%20small.png College chemistry, 1983

Derek Lowe The 2002 Model

Dbl%20new%20portrait%20B%26W.png After 10 years of blogging. . .

Derek Lowe, an Arkansan by birth, got his BA from Hendrix College and his PhD in organic chemistry from Duke before spending time in Germany on a Humboldt Fellowship on his post-doc. He's worked for several major pharmaceutical companies since 1989 on drug discovery projects against schizophrenia, Alzheimer's, diabetes, osteoporosis and other diseases. To contact Derek email him directly: derekb.lowe@gmail.com Twitter: Dereklowe

Chemistry and Drug Data: Drugbank
Emolecules
ChemSpider
Chempedia Lab
Synthetic Pages
Organic Chemistry Portal
PubChem
Not Voodoo
DailyMed
Druglib
Clinicaltrials.gov

Chemistry and Pharma Blogs:
Org Prep Daily
The Haystack
Kilomentor
A New Merck, Reviewed
Liberal Arts Chemistry
Electron Pusher
All Things Metathesis
C&E News Blogs
Chemiotics II
Chemical Space
Noel O'Blog
In Vivo Blog
Terra Sigilatta
BBSRC/Douglas Kell
ChemBark
Realizations in Biostatistics
Chemjobber
Pharmalot
ChemSpider Blog
Pharmagossip
Med-Chemist
Organic Chem - Education & Industry
Pharma Strategy Blog
No Name No Slogan
Practical Fragments
SimBioSys
The Curious Wavefunction
Natural Product Man
Fragment Literature
Chemistry World Blog
Synthetic Nature
Chemistry Blog
Synthesizing Ideas
Business|Bytes|Genes|Molecules
Eye on FDA
Chemical Forums
Depth-First
Symyx Blog
Sceptical Chymist
Lamentations on Chemistry
Computational Organic Chemistry
Mining Drugs
Henry Rzepa


Science Blogs and News:
Bad Science
The Loom
Uncertain Principles
Fierce Biotech
Blogs for Industry
Omics! Omics!
Young Female Scientist
Notional Slurry
Nobel Intent
SciTech Daily
Science Blog
FuturePundit
Aetiology
Gene Expression (I)
Gene Expression (II)
Sciencebase
Pharyngula
Adventures in Ethics and Science
Transterrestrial Musings
Slashdot Science
Cosmic Variance
Biology News Net


Medical Blogs
DB's Medical Rants
Science-Based Medicine
GruntDoc
Respectful Insolence
Diabetes Mine


Economics and Business
Marginal Revolution
The Volokh Conspiracy
Knowledge Problem


Politics / Current Events
Virginia Postrel
Instapundit
Belmont Club
Mickey Kaus


Belles Lettres
Uncouth Reflections
Arts and Letters Daily
In the Pipeline: Don't miss Derek Lowe's excellent commentary on drug discovery and the pharma industry in general at In the Pipeline

In the Pipeline

« Enhancing the Brain: Here We Go | Main | Floppiness Is Not Your Friend: Who Knew? »

December 9, 2008

Goldman Sachs: A New Drug Research Model?

Email This Entry

Posted by Derek

Now, here’s an odd item from the Financial Times (registration required):

Goldman Sachs is in talks to provide hundreds of millions of dollars of funding to a large pharmaceutical company, in the first evidence of a new business model for the sector that will see financing shifted away from funding companies and towards targeted co-development of specific medicines. . .

. . .(The model involves) a different approach, creating a "research pool" into which pharma companies would place a range of experimental drugs in a single therapeutic area in early-stage phase 1 and 2 trials, where their specialists would work alongside external experts including scientists, chemists and clinical research organizations.

This was announced at a conference run by the newspaper, so they’re really the only source for information on this. I haven’t been able to find anything from Goldman about it, for example, and the minimal press coverage so far has all pointed back to this article. (Ed Silverman picked it up at Pharmalot, for example).

So one wonders what’s up, because the information that’s given raises more questions than it answers. I presume that the assumption is that since only a few early-stage clinical compounds ever make it, that this gives everyone a chance to share the risk. But which therapeutic area are we talking about here? How are things apportioned when one compound makes it through? And what if more than one does? And where are these external experts coming from, and who pays them?

This could be very interesting, because I think that we need to be open to some new research models in the industry. The current one isn’t exactly spewing results these days. But I wish that I knew more about what this proposal involves – anyone out there have any more details that they can share?

Comments (12) + TrackBacks (0) | Category: Business and Markets | Clinical Trials | Drug Development


COMMENTS

1. Jose on December 9, 2008 2:26 PM writes...

Pharma Skunk Works? Pharma Peenemünde?

Permalink to Comment

2. Satan on December 9, 2008 3:08 PM writes...

But why do we require Goldman Sachs when big pharma has already dug it's own grave? Should they not concentrate on their core mission- destroying our economy with bigger ponzi schemes?

Permalink to Comment

3. David on December 9, 2008 4:23 PM writes...

I believe that Lilly did something similar with an alzheimer's drug in development.

Permalink to Comment

4. Skeptic on December 10, 2008 12:39 AM writes...

Satan, Goldman Sachs will soon create an economic boom in wheelbarrows and stoves to burn all the worthless US fiat.

Good thing Derek focuses on the real criminals like Kevin Trudeau and Matthias Rath...WINK WINK.

Permalink to Comment

5. Lewis Daivdon on December 10, 2008 1:51 AM writes...

Now it looks like GTHR GeneThera will be the one getting bought. From sources two companies OXB.L and SASY.PA are showing major intrest in GTHR. Now GTHR revised a proposal .With its stock price at a all time low. A buyout would soar the share price to over $19.00 a share in no time.What does GTHR hold that brings so much value to it from other companies.

Website:http://www.genethera.net/index.htm

Oxford BioMedica Leaps on Rejected Buyout Bid from (GTHR.PK)

http://www.reuters.com/article/marketsNews/idINLF72702420080815

›Fri Aug 15, 2008 7:55am EDT
By Ben Hirschler

LONDON, Aug 15 (Reuters) - Oxford BioMedica Plc (OXB.L) shares leapt more than 20 percent on Friday after it became the latest company to receive a takeover approach in the increasingly active biotech sector.

The gene therapy specialist, however, said it had rejected a bid approach from GeneThera Inc (GTHR.PK) as not credible.

GeneThera, a U.S. company whose shares are traded over the counter, has a market capitalisation of just $230,000, while Oxford BioMedica was worth 46.5 million pounds ($87 million) as of Thursday’s market close.

Oxford BioMedica said GeneThera had first indicated its interest in acquiring the company in July and had made a revised proposal on Aug. 14.

“The board of Oxford BioMedica, which has consulted with its advisors, JP Morgan Cazenove and Rothschild, remains of the view that this unsolicited approach is not credible and is not in the interests of its shareholders,” the British-based company said.

Still, news of the approach reignited speculation about the future of the group and the possibility of offers from other companies, in the light of the quickening pace of takeover activity in the biotechnology industry.

Shares in Oxford BioMedica — which suffered a major setback in July when its key experimental cancer vaccine TroVax failed a trial in kidney cancer — were 24 percent higher at 10.75 pence by 1140 GMT, though still well off their year high of 30.5p.

TroVax is partnered with France’s Sanofi-Aventis.

Oxford BioMedica is the second small British biotech in two days to announce bid interest. Shares in Protherics Plc (PRCS.L) surged more than 40 percent on Thursday after it said it had received several bid approaches.

Biotechnology is receiving increased attention from big pharma companies hunting for new products to refill their dwindling new-drug pipelines.

Last month, Sanofi agreed to buy British vaccine firm Acambis Plc (ACM.L) for around $550 million, or a 64 percent premium to the prevailing share price.

And in the United States two giant takeover battles are under way, with Roche bidding $43.7 billion for the rest of Genentech (DNA) it does not already own and Bristol-Myers Squibb’s (BMY) offering $5.2 billion for ImClone Systems (IMCL). Both offers have been rejected as inadequate.‹

Permalink to Comment

6. RZ on December 10, 2008 2:46 PM writes...

This looks a lot like what Symphony Capital has been doing for quite some time (with Exelixis, Isis, Dynavax, etc).

http://www.symphonycapital.com

They spin off small buckets of development candidates into a new and separate corporate entity which they finance. The spinoff pays the salaries of the people in the parent company who are working on the portfolio, and all of the external R&D costs for the portfolio (e.g. CRO costs), but the work itself stays largely within the physical walls of the parent company.

The parent company has a right to buy the spinoff "company" (and its assets) back from Symphony at a significant markup after crtical value-add milestones are reached.

It's an interesting alternative way for mid-size companies who have more pipeline than they can manage to maximize the value of the pipeline rather than entering into early big-pharma partnerships which force the small partner to give away enormous fractions of the upside value.

Simultaneously, the parent company offloads a lot of the development risk, because if the portfolio fails, the parent company just walks away from those assets (i.e., chooses not to "buy back" the spinoff), and the lost R&D cost is eaten by the Symphony investors.

Permalink to Comment

7. Cellbio on December 10, 2008 11:53 PM writes...

No details, but lots of interest in the concept. I am working with several others on trying to build this model for early assets, either coming from academic labs, and really needing help before a company is formed, or working with existing bug pharma/biotech assets that are stalled for any number of reasons, including lack of money, lack of conviction, poor strategic fit or the belief in the value of less bureaucratic shops to do the early work to prove some merit.

So far, everyone likes the concept, but no funding yet. The details of how one constructs ownership in the assets is murky. Thanks for the info re Symphony, it is a very relevant model.

Permalink to Comment

8. steve smith on December 19, 2008 2:40 PM writes...

Many VCs are doing this. For exmaple, QuakerBio Ventures in Phila.

Permalink to Comment

9. Anonymous on March 22, 2009 10:15 AM writes...

Stem Cell Innovations (scll) www.activtox.com

Permalink to Comment

10. mariage on September 30, 2011 10:27 AM writes...

Apparently this page doesnt load successfully on a Dell Streak. Are other people having the same exact trouble ?

Permalink to Comment

11. Kent Niksich on January 7, 2013 4:21 PM writes...

Hey there! This post couldn't be written any better! Reading this post reminds me of my good old room mate! He always kept chatting about this. I will forward this page to him. Fairly certain he will have a good read. Thanks for sharing!

Permalink to Comment

12. Daren Rajtar on March 29, 2014 12:45 PM writes...

On the subject of "Questions around community rights in clinical trials" Dr. Raju Kucherlapati asks "How do you define the community?" and whether that community is at the national or international level ...

Permalink to Comment

POST A COMMENT




Remember Me?



EMAIL THIS ENTRY TO A FRIEND

Email this entry to:

Your email address:

Message (optional):




RELATED ENTRIES
XKCD on Protein Folding
The 2014 Chemistry Nobel: Beating the Diffraction Limit
German Pharma, Or What's Left of It
Sunesis Fails with Vosaroxin
A New Way to Estimate a Compound's Chances?
Meinwald Honored
Molecular Biology Turns Into Chemistry
Speaking at Northeastern